Promoter Methylation Blocks FES Protein-tyrosine Kinase Gene Expression in Colorectal Cancer

被引:15
作者
Shaffer, Jonathan M. [1 ]
Smithgall, Thomas E. [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15261 USA
关键词
MYELOID-LEUKEMIA CELLS; C-FES; DNA METHYLATION; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; BINDING-SITE; COLON-CANCER; FPS/FES; IDENTIFICATION; PROTOONCOGENE;
D O I
10.1002/gcc.20638
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The FES locus encodes a unique nonreceptor protein-tyrosine kinase (FES) traditionally viewed as a proto-oncogene but more recently implicated as a tumor suppressor in colorectal cancer (CRC). Recent studies have demonstrated that while FES is expressed in normal colonic epithelium, expression is lost in tumor tissue and colorectal cancer cell lines, a finding common among tumor suppressors. Here we provide compelling evidence that promoter methylation is an important mechanism responsible for downregulation of FES gene expression in colorectal cancer cells. Treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine resulted in the expression of functional FES transcripts in all CRC cell lines examined, including Caco-2, COLO 320, DLD-1, HCT 116, SNU-1040, SW-480, and HT-29. Bisulfite sequencing of genomic DNA isolated from 5-aza-2'-deoxycytidine-treated HT-29 cells identified methylated CpG dinucleotides immediately upstream from the FES transcription initiation sites. In contrast, this region of the FES promoter was hypomethylated in genomic DNA from normal colonic epithelium. In addition, methylation completely blocked the activity of the FES promoter in reporter gene assays. Promoter methylation is a previously unrecognized mechanism by which FES expression is suppressed in CRC cell lines, and is consistent with a tumor suppressor role for FES in this tumor site despite its tyrosine kinase activity. (c) 2008 Wiley-Liss, Inc.
引用
收藏
页码:272 / 284
页数:13
相关论文
共 44 条
[1]  
ALCALAY M, 1990, ONCOGENE, V5, P267
[2]   Mutational analysis of the tyrosine kinome in colorectal cancers [J].
Bardelli, A ;
Parsons, DW ;
Silliman, N ;
Ptak, J ;
Szabo, S ;
Saha, S ;
Markowitz, S ;
Willson, JKV ;
Parmigiani, G ;
Kinzler, KW ;
Vogelstein, B ;
Velculescu, VE .
SCIENCE, 2003, 300 (5621) :949-949
[3]   Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J].
Baylin, SB ;
Ohm, JE .
NATURE REVIEWS CANCER, 2006, 6 (02) :107-116
[4]   DNA METHYLATION INHIBITS TRANSCRIPTION INDIRECTLY VIA A METHYL-CPG BINDING-PROTEIN [J].
BOYES, J ;
BIRD, A .
CELL, 1991, 64 (06) :1123-1134
[5]  
Cheng HY, 1999, MOL CELL BIOL, V19, P8335
[6]   A point mutation in the N-terminal coiled-coil domain releases c-Fes tyrosine kinase activity and survival signaling in myeloid leukemia cells [J].
Cheng, HY ;
Schiavone, AP ;
Smithgall, TE .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (18) :6170-6180
[7]   5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation:: mechanistic studies and their implications for cancer therapy [J].
Christman, JK .
ONCOGENE, 2002, 21 (35) :5483-5495
[8]   A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins [J].
Cross, SH ;
Meehan, RR ;
Nan, XS ;
Bird, A .
NATURE GENETICS, 1997, 16 (03) :256-259
[9]   A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer [J].
Delfino, FJ ;
Stevenson, H ;
Smithgall, TE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (13) :8829-8835
[10]   The KRAB-associated co-repressor KAP-1 is a coiled-coil binding partner, substrate and activator of the c-Fes protein tyrosine kinase [J].
Delfino, Frank J. ;
Shaffer, Jonathan M. ;
Smithgall, Thomas E. .
BIOCHEMICAL JOURNAL, 2006, 399 :141-150